3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
6
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
23
Neoplasm Metastasis
9
Squamous Cell Carcinoma of Head and Neck
3
Triple Negative Breast Neoplasms
2
Recurrence
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms
2
Melanoma
2
Lymphangioma
2
Hyperglycemia
2
Head and Neck Squamous Cell Cancer
2
Vascular Malformations
1
Uveal Melanoma
1
Stomach Neoplasms
1
Solid Tumor
1
Skin Diseases, Vascular
1
Sarcoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Oropharyngeal Neoplasms
1
Multiple Endocrine Neoplasia Type 1
1
Meningioma
1
Lymphatic Abnormalities
1
Lymphangioma, Cystic
1
Hormone Receptor Positive Breast Carcinoma
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Exanthema
1
Interventions
Everolimus
5
Cetuximab
2
volagidemab
1
tanezumab
1
pembrolizumab
1
inavolisib
1
Vemurafenib
1
Trimetazidine
1
Sirolimus
1
Secretin
1
SF 1126
1
Pharmaceutical Preparations
1
Panobinostat
1
Oxaliplatin
1
Nivolumab
1
NVP-BKM120
1
Leucovorin
1
Irinotecan
1
Fulvestrant
1
Fluorouracil
1
Drug Therapy
1
Capecitabine
1
CB-839
1
CA-19-9 Antigen
1
Bevacizumab
1
Aspirin
1
Alpelisib
1
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Hereditary Sensory and Autonomic Neuropathies
×
Alpelisib
×
Clear all
NCT03386162
2022-11-28
SAFIR-PI3K
UNICANCER
Phase 2
Terminated
31 enrolled